AORT vs SGP: stock comparison and AI forecast
Artivion, Inc. (AORT) and Spyglass Pharma, Inc. (SGP) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AORT Artivion, Inc.
- Market Cap
- $1.16B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
SGP Spyglass Pharma, Inc.
- Market Cap
- $1.13B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- AORT and SGP have similar market capitalizations ($1.16B and $1.13B).
- AORT carries 0.97 times debt per unit of equity, against 0.05 times for SGP.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AORT | SGP |
|---|---|---|
| Market Cap | $1.16B | $1.13B |
| P/B Ratio | 2.58x | 4.84x |
| EPS | $-0.10 | – |
| Book Value/Share | $9.19 | $6.95 |
| Revenue/Share | $9.67 | – |
| FCF/Share | $-0.19 | – |
Profitability & Margins
| Metric | AORT | SGP |
|---|---|---|
| Gross Margin | 64.4% | – |
| Operating Margin | 4.5% | – |
| EBT Margin | 0.5% | – |
| Tax Rate | 241.7% | – |
Financial Health
| Metric | AORT | SGP |
|---|---|---|
| Current Ratio | 3.47x | 25.06x |
| Quick Ratio | 2.51x | – |
| D/E Ratio | 0.97x | 0.05x |
| Financial Leverage | – | 1.05x |
| Interest Coverage | 0.5x | – |
| Working Capital | $264M | $227M |
Cash Flow
| Metric | AORT | SGP |
|---|---|---|
| Operating Cash Flow | $42M | – |
| Free Cash Flow | -$9M | – |
| Capital Spending | -$51M | – |
| OCF Growth YoY | 112.2% | – |
| FCF Growth YoY | -219.5% | – |
| FCF/Sales | -1.9% | – |
| CapEx/Sales | 10.8% | – |
Operational Efficiency
| Metric | AORT | SGP |
|---|---|---|
| Receivables Turnover | 4.8x | – |
| Inventory Turnover | 1.6x | – |
| Fixed Assets Turnover | 6.4x | – |
| Days Sales Outstanding | 76 days | – |
| Days Inventory | 225 days | – |
| Payables Period | 45 days | – |
| Cash Conversion Cycle | 255 days | – |
Income Statement
| Metric | AORT | SGP |
|---|---|---|
| Total Revenue | $471M | – |
| Operating Income | $21M | – |
| R&D Expense | $35M | – |
| SG&A Expense | $255M | – |
| Cost of Goods Sold | $168M | – |
Dividend & Shareholder Information
| Metric | AORT | SGP |
|---|---|---|
| Shares Outstanding | 49M | 33M |
AORT vs SGP: stock comparison and AI forecast
Which is bigger, AORT or SGP?
AORT and SGP have similar market capitalizations ($1.16B and $1.13B).
Which one does Intratio's AI model rank higher, AORT or SGP?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.